Basic Information
Genmab is a publicly traded international biotechnology company specializing in the creation and development of differentiated antibody therapies for the treatment of cancer. Founded in 1999, the company has two approved antibodies, a broad clinical and preclinical product pipeline, and three proprietary next-generation antibody technologies.
Genmab A/S
Copenhagen,TheCapitalRegionofDenmark,Denmark
more than 500 people
January 01, 1999
info@genmab.com
Enterprise Profile
Industrial Sector
Technology
Concept
Application Scenarios